April 22, 1983

Treatment of Autoimmune Hemolytic Anemia With Vinca-Loaded Platelets

Author Affiliations

From the Department of Medicine, Center for Blood Diseases, University of Miami School of Medicine, and Medical and Research Services, Veterans Administration Hospital, Miami.

JAMA. 1983;249(16):2189-2194. doi:10.1001/jama.1983.03330400035021

We worked with a new strategy for the treatment of autoimmune hemolytic anemia (AIHA) of the warm antibody type. Platelets were loaded with Vinca alkaloids and reacted with antiplatelet antibodies to facilitate their phagocytosis by macrophages, resulting in a measure of selective delivery of the drugs to the cells of the mononuclear phagocyte system, which destroy RBCs in AIHA. Four patients were studied. Three with AIHA refractory to splenectomy and the use of moderate doses of glucocorticoids achieved hematologic and clinical remissions. Administration of steroids was either discontinued or reduced to minimal doses after treatment. Remissions lasted three years in two patients and one year in the other. Responses were characterized by prompt prolongation of RBC survival, correction of anemia, and gradual decrease in cell-bound antibody. In one nonsplenectomized patient, the disorder did not respond. Platelet— Vinca alkaloid complex is useful in the treatment of AIHA refractory to splenectomy and use of steroids.

(JAMA 1983;249:2189-2194)